Insider Transactions in Q4 2021 at Ardelyx, Inc. (ARDX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 15
2021
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,211,352
-12.52%
|
$1,211,352
$1.14 P/Share
|
|
Dec 15
2021
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,211,352
-12.52%
|
$1,211,352
$1.14 P/Share
|
|
Dec 14
2021
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,735
-7.72%
|
$1,000,735
$1.24 P/Share
|
|
Dec 14
2021
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,000,735
-7.72%
|
$1,000,735
$1.24 P/Share
|
|
Dec 09
2021
|
Forest Baskett > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
669,483
-4.91%
|
$669,483
$1.51 P/Share
|
|
Dec 09
2021
|
Scott D Sandell > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
669,483
-4.91%
|
$669,483
$1.51 P/Share
|
|
Nov 22
2021
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
537
-0.19%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
Robert Blanks Officer |
SELL
Open market or private sale
|
Direct |
643
-0.18%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
Jeffrey W Jacobs Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,754
-2.31%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
Michael Raab President & CEO |
SELL
Open market or private sale
|
Direct |
2,607
-0.41%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
Justin A Renz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
643
-0.22%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
Susan Rodriguez Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
643
-0.33%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Indirect |
184
-0.2%
|
$0
$0.99 P/Share
|
|
Nov 22
2021
|
David P. Rosenbaum Chief Development Officer |
SELL
Open market or private sale
|
Direct |
643
-0.21%
|
$0
$0.99 P/Share
|
|
Nov 15
2021
|
Jeffrey W Jacobs Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.84%
|
$5,000
$1.13 P/Share
|
|
Nov 12
2021
|
Elizabeth A Grammer Officer |
SELL
Open market or private sale
|
Direct |
77,432
-21.88%
|
$77,432
$1.12 P/Share
|
|
Nov 08
2021
|
Jeffrey W Jacobs Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,166
-1.64%
|
$2,166
$1.18 P/Share
|
|
Oct 08
2021
|
Elizabeth A Grammer Officer |
SELL
Grant, award, or other acquisition
|
Direct |
250,000
-41.4%
|
-
|
|
Oct 08
2021
|
Justin A Renz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+45.93%
|
-
|
|
Oct 08
2021
|
Robert Blanks Officer |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+40.88%
|
-
|
|
Oct 08
2021
|
Susan Rodriguez Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+43.14%
|
-
|
|
Oct 08
2021
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
60,000
+39.78%
|
-
|
|
Oct 08
2021
|
David P. Rosenbaum Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+32.48%
|
-
|
|
Oct 08
2021
|
Michael Raab President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+32.11%
|
-
|